Using radiomics-based modelling to predict individual progression from mild cognitive impairment to Alzheimer's disease
Creators
- 1. Institute of Biomedical Engineering, School of Life Science, Shanghai University, Shanghai (China)
- 2. Department of Nuclear Medicine, University Hospital Bern, Bern (Switzerland)
- 3. Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing (China)
- 4. Human Phenome Institute, Fudan University, Shanghai (China)
- 5. PET Center, Huashan Hospital, Fudan University, Shanghai (China)
- 6. National Clinical Research Center for Geriatric Disorders, Beijing (China)
- 7. School of Biomedical Engineering, Hainan University, Haikou (China)
- 8. Center of Alzheimer's Disease, Beijing Institute for Brain Disorders, Beijing (China)
- 9. Department of Informatics, Technische Universität München, Munich (Germany)
Description
Predicting the risk of disease progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD) has important clinical significance. This study aimed to provide a personalized MCI-to-AD conversion prediction via radiomics-based predictive modelling (RPM) with multicenter 18F-fluorodeoxyglucose positron emission tomography (FDG PET) data. FDG PET and neuropsychological data of 884 subjects were collected from Huashan Hospital, Xuanwu Hospital, and from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. First, 34,400 radiomic features were extracted from the 80 regions of interest (ROIs) for all PET images. These features were then concatenated for feature selection, and an RPM model was constructed and validated on the ADNI dataset. In addition, we used clinical data and the routine semiquantification index (standard uptake value ratio, SUVR) to establish clinical and SUVR Cox models for further comparison. FDG images from local hospitals were used to explore RPM performance in a separate cohort of individuals with healthy controls and different cognitive levels (a complete AD continuum). Finally, correlation analysis was conducted between the radiomic biomarkers and neuropsychological assessments. The experimental results showed that the predictive performance of the RPM Cox model was better than that of other Cox models. In the validation dataset, Harrell's consistency coefficient of the RPM model was 0.703 ± 0.002, while those of the clinical and SUVR models were 0.632 ± 0.006 and 0.683 ± 0.009, respectively. Moreover, most crucial imaging biomarkers were significantly different at different cognitive stages and significantly correlated with cognitive disease severity. The preliminary results demonstrated that the developed RPM approach has the potential to monitor progression in high-risk populations with AD.
Availability note (English)
Available from: http://dx.doi.org/10.1007/s00259-022-05687-yAdditional details
Identifiers
Publishing Information
- Journal Title
- European Journal of Nuclear Medicine and Molecular Imaging
- Journal Volume
- 49
- Journal Issue
- 7
- Journal Page Range
- p. 2163-2173
- ISSN
- 1619-7070
- CODEN
- EJNMA6
INIS
- Country of Publication
- Germany
- Country of Input or Organization
- Germany
- INIS RN
- 53077767
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- BIOLOGICAL MARKERS; COMPARATIVE EVALUATIONS; COMPUTERIZED SIMULATION; CORRELATIONS; DATA COMPILATION; DATASETS; FLUORINE 18; FLUORODEOXYGLUCOSE; IMAGE PROCESSING; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; PERFORMANCE; POSITRON COMPUTED TOMOGRAPHY; RADIOMICS; RADIOPHARMACEUTICALS; UPTAKE; VALIDATION
- Descriptors DEC
- ANTIMETABOLITES; BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; COMPUTERIZED TOMOGRAPHY; DATA; DATA PROCESSING; DIAGNOSTIC TECHNIQUES; DISEASES; DOCUMENT TYPES; DRUGS; EMISSION COMPUTED TOMOGRAPHY; EVALUATION; FLUORINE ISOTOPES; HOURS LIVING RADIOISOTOPES; INFORMATION; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; LABELLED COMPOUNDS; LIGHT NUCLEI; MATERIALS; MEDICINE; NANOSECONDS LIVING RADIOISOTOPES; NUCLEAR MEDICINE; NUCLEI; ODD-ODD NUCLEI; PROCESSING; RADIOACTIVE MATERIALS; RADIOISOTOPES; RADIOLOGY; SIMULATION; TESTING; TOMOGRAPHY
Optional Information
- Funding organization
- Alzheimer's Disease Neuroimaging Initiative (United States)